Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

Archive for 26 dicembre 2017

Batu Biologics Successfully Completes $1.3 Million Starvethetumor Equity Crowdfunding Campaign

Posted by fidest press agency su martedì, 26 dicembre 2017

Natali a New York (2)New York. Batu Biologics, an immuno-oncology Company dedicated to the development of its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax™, announced today the successful closure of a regulation 506(c) equity crowdfunding offering bringing in $1.3 Million in capital to the Company.
The proceeds of this offering were initially earmarked for IND-enabling experiments, when the offering was launched on EquityNet in May of 2017. In early November of this year, Batu Biologics announced the clearance of the Investigational New Drug Application (#16296) for the ValloVax immune therapy. Based upon the successful completion of this milestone, the remaining proceeds from this offering will be used to upscale GMP manufacturing in preparation for the Company’s Phase I study and to position the Company to secure partnerships to demonstrate clinical proof of concept for the ValloVax program.
“We would like to graciously thank our shareholders and collaborators for the support of our vision in the development of the ValloVax immune therapy,” stated Samuel C. Wagner, President and CEO of Batu Biologics. “2018 will be a landmark year for Batu Biologics with the goal of establishing safety and feasibility of ValloVax in a pilot clinical study in all solid tumors, and to further elucidate the mechanism of action of our novel placentally-derived immune therapy.”ValloVax targets angiogenesis, or blood vessel formation, which is a biological process that is commonly found in all solid tumors. Instead of targeting the tumor itself, which can be a difficult strategy due to cancer’s propensity to mutate, ValloVax trains the body to initiate a cellular and antibody response against several targets associated with tumor angiogenesis. To date, ValloVax has demonstrated strong inhibition of melanoma, lung cancer, colorectal cancer, breast cancer, and glioblastoma in animal models as a standalone therapy. However, by facilitating better drug delivery and lymphocyte penetration into the tumor, ValloVax may be an ideal candidate for combination therapies with some of the latest immuno-oncology drugs.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

NodeSource Secures $17.5 Million in Series B Funding

Posted by fidest press agency su martedì, 26 dicembre 2017

Silicon Valley BankThe up-round investment was provided by Silicon Valley Bank, Industry Ventures and existing investors Crosslink Capital and RRE Ventures. NodeSource will harness the investment proceeds to rapidly grow its engineering, support and global go-to-market teams to better serve customers as they create and deploy mission-critical and secure applications, leveraged by the power and low cost of the open source community.NodeSource has raised a total of $33.4 million since its founding in 2014, including a $12.5 million Series A round in April 2016 by RRE Ventures, Crosslink Capital and Resolute Ventures and a February 2015 seed round of $3.4 million from Crosslink Capital, Hack VC and Resolute Ventures.
Node.js is the fastest-growing open source project on earth, and NodeSource is the only commercial provider specializing in Node.js for the enterprise. Its flagship product N|Solid is a fully-compatible enhanced Node.js platform designed for mission-critical enterprise applications and is built to meet the unique needs associated with running server-side JavaScript at scale. N|Solid empowers organizations to develop, manage, secure, and analyze Node.js applications while providing unparalleled visibility into application behavior and system health, as well as offering configurable security policies and real-time vulnerability scanning. NodeSource’s effective commercialization of Node.js technology has attracted a wide range of customers, including Citadel, Comcast, Condé Nast, Delta Airlines, Goldman Sachs, Mastercard, and PayPal.“Our Node.js solutions are powerful tools for enterprises that need to run mission-critical applications on JavaScript,” commented NodeSource Founder and CEO Joe McCann. “The market potential is significant, and this Series B investment from our partners at Crosslink Capital, Industry Ventures, Silicon Valley Bank and RRE Ventures further validates the strategy behind N|Solid and NodeSource Certified Modules (NCM), which is all about empowering organizations to successfully adopt, operationalize and scale Node.js to drive digital transformation initiatives.” (photo: Silicon Valley Bank)

Posted in Economia/Economy/finance/business/technology, Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »